An Open-Label, Dose-Escalation Phase I/II Study of PRI-724 for Patients With Advanced Myeloid Malignancies

Trial Profile

An Open-Label, Dose-Escalation Phase I/II Study of PRI-724 for Patients With Advanced Myeloid Malignancies

Completed
Phase of Trial: Phase I/II

Latest Information Update: 05 May 2017

At a glance

  • Drugs PRI 724 (Primary) ; Cytarabine; Dasatinib
  • Indications Acute myeloid leukaemia; Chronic myeloid leukaemia; Essential thrombocythaemia; Myelodysplastic syndromes; Myelofibrosis; Polycythaemia vera
  • Focus Adverse reactions
  • Sponsors PRISM Pharma Co
  • Most Recent Events

    • 02 May 2017 Status changed from active, no longer recruiting to completed.
    • 19 Apr 2016 Planned End Date changed from 1 Oct 2015 to 1 Dec 2016.
    • 19 Apr 2016 Planned primary completion date changed from 1 Oct 2015 to 1 Dec 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top